Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique 'two-modes' inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human α-thrombin:synthetic-variegin complex at 2.4 Å resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants.

Original publication

DOI

10.1371/journal.pone.0026367

Type

Journal article

Journal

PLoS One

Publication Date

2011

Volume

6

Keywords

Amino Acid Sequence, Animals, Antithrombins, Binding Sites, Biocatalysis, Crystallography, X-Ray, Drug Design, Hirudins, Humans, Kinetics, Models, Molecular, Molecular Sequence Data, Mutant Proteins, Peptide Fragments, Peptides, Salivary Proteins and Peptides, Static Electricity, Thrombin, Zebrafish